BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 26510945)

  • 1. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
    Zou M; Zhang X; Xu C
    Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer.
    Rajoria S; Suriano R; George A; Shanmugam A; Schantz SP; Geliebter J; Tiwari RK
    PLoS One; 2011 Jan; 6(1):e15879. PubMed ID: 21267453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.
    Ataie-Kachoie P; Morris DL; Pourgholami MH
    PLoS One; 2013; 8(4):e60817. PubMed ID: 23593315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
    Kandala PK; Srivastava SK
    BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 and ERK Signaling Pathways Are Implicated in the Invasion Activity by Oncostatin M through Induction of Matrix Metalloproteinases 2 and 9.
    Ko HS; Park BJ; Choi SK; Kang HK; Kim A; Kim HS; Park IY; Shin JC
    Yonsei Med J; 2016 May; 57(3):761-8. PubMed ID: 26996579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.
    Li WX; Chen LP; Sun MY; Li JT; Liu HZ; Zhu W
    Oncotarget; 2015 Sep; 6(27):23776-92. PubMed ID: 26068982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
    Cheung LW; Leung PC; Wong AS
    Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    Jia ZH; Jia Y; Guo FJ; Chen J; Zhang XW; Cui MH
    PLoS One; 2017; 12(8):e0183622. PubMed ID: 28859117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitidine chloride inhibits ovarian cancer cell migration and invasion by suppressing MMP-2/9 production via the ERK signaling pathway.
    Sun X; Lin L; Chen Y; Liu T; Liu R; Wang Z; Mou K; Xu J; Li B; Song H
    Mol Med Rep; 2016 Apr; 13(4):3161-8. PubMed ID: 26935265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitory effects of matrix metalloproteinase (MMP) inhibitor LY52 on expression of MMP-2 and MMP-9 and invasive ability of human ovarian carcinoma cell line SKOV3].
    Yuan YX; Xu WF; Liu J; Chen MH; Meng H; Qu XJ
    Ai Zheng; 2006 Jun; 25(6):663-70. PubMed ID: 16764758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpinetin inhibits proliferation and migration of ovarian cancer cells via suppression of STAT3 signaling.
    Zhao X; Guo X; Shen J; Hua D
    Mol Med Rep; 2018 Oct; 18(4):4030-4036. PubMed ID: 30132572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells.
    Wang Y; Li L; Guo X; Jin X; Sun W; Zhang X; Xu RC
    Cytokine; 2012 Aug; 59(2):228-36. PubMed ID: 22595649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of high glucose on metastasis of colon cancer cells.
    Lin CY; Lee CH; Huang CC; Lee ST; Guo HR; Su SB
    World J Gastroenterol; 2015 Feb; 21(7):2047-57. PubMed ID: 25717237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma.
    Cao HH; Chu JH; Kwan HY; Su T; Yu H; Cheng CY; Fu XQ; Guo H; Li T; Tse AK; Chou GX; Mo HB; Yu ZL
    Sci Rep; 2016 Feb; 6():21731. PubMed ID: 26911838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.
    Fishman DA; Liu Y; Ellerbroek SM; Stack MS
    Cancer Res; 2001 Apr; 61(7):3194-9. PubMed ID: 11306508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitro.
    Chen L; Liu T; Zhang S; Zhou J; Wang Y; Di W
    J Ovarian Res; 2014 Dec; 7():115. PubMed ID: 25491408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
    Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
    Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloprost, a prostacyclin analog, inhibits the invasion of ovarian cancer cells by downregulating matrix metallopeptidase-2 (MMP-2) through the IP-dependent pathway.
    Ahn JH; Lee KT; Choi YS; Choi JH
    Prostaglandins Other Lipid Mediat; 2018 Jan; 134():47-56. PubMed ID: 29292033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitory effects of antisense MMP-9 oligodeoxynucleotides on invasiveness and adherence of ovarian cancer cells].
    Hu XX; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):662-5. PubMed ID: 17274370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.